ViroNovative BV (ViroNovative) is a privately held pharmaceutical company engaged in providing a complete solution to human Metapneumovirus (hMPV), a virus discovered at the department of virology in 2001. The company is involved in developing diagnostics, antivirals and vaccines for the detection, prevention and treatment of hMPV infection. ViroNovative is a spin out formed under the new active incubator policy of Erasmus University Rotterdam. It is an active member of Viroventures, where it is in collaboration with Viroscope and ViroClinics to share the resources and expertise to fight against infectious diseases. The company entered into a worldwide licensing agreement with Diagnostic HYBRIDS for rapid detection of hMPV. ViroNovative is headquartered in GE Rotterdam, the Netherlands.